Daphne Guh Selected Research

Hydromorphone (Dilaudid)

1/2021	Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.
12/2020	Physician Communication in Injectable Opioid Agonist Treatment: Collecting Patient Ratings With the Communication Assessment Tool.
9/2019	Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder.
1/2019	Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
6/2018	The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder.
1/2018	Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
1/2018	Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
1/2017	Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
5/2016	Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
6/2010	Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daphne Guh Research Topics

Disease

16	Opioid-Related Disorders (Opiate Addiction) 01/2021 - 06/2009
5	Rheumatoid Arthritis 09/2017 - 06/2005
2	Pain (Aches) 04/2022 - 02/2012
2	Substance-Related Disorders (Drug Abuse) 01/2022 - 01/2012
2	Opiate Overdose 09/2019 - 01/2017
2	Heroin Dependence (Heroin Abuse) 02/2015 - 06/2009
1	Chronic Pain 04/2022
1	Neuralgia (Stump Neuralgia) 04/2022
1	Out-of-Hospital Cardiac Arrest 12/2020
1	COVID-19 12/2020
1	Sleepiness 09/2019
1	Tobacco Use Disorder (Nicotine Dependence) 06/2018
1	Spondylarthropathies 10/2017
1	Axial Spondyloarthritis 10/2017
1	Fatigue 02/2012
1	HIV Infections (HIV Infection) 05/2010
1	Seizures (Absence Seizure) 08/2009
1	Vitelliform Macular Dystrophy 06/2009
1	Spinal Cord Compression 11/2006

Drug/Important Bio-Agent (IBA)

15	Heroin (Diamorphine)IBA 01/2021 - 06/2009
14	Opioid Analgesics (Opioids)IBA 01/2022 - 06/2009
11	Hydromorphone (Dilaudid)FDA LinkGeneric 01/2021 - 05/2010
3	ametantrone (HAQ)IBA 02/2012 - 06/2005
3	Methadone (Dolophine)FDA LinkGeneric 09/2010 - 06/2009
2	Naloxone (Narcan)FDA LinkGeneric 09/2019 - 01/2017
1	antineoplaston A10 (A 10)IBA 04/2022
1	Ketamine FDA LinkGeneric 04/2022
1	Cocaine (Cocaine HCl)IBA 01/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2017
1	Opiate AlkaloidsIBA 06/2009
1	Pharmaceutical PreparationsIBA 06/2009
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 06/2009
1	Adalimumab (Humira)FDA Link 09/2008
1	Prescription DrugsIBA 08/2007

Therapy/Procedure

12	Injections 01/2022 - 08/2009
2	Therapeutics 08/2009 - 06/2009
1	Resuscitation 12/2020
1	Defibrillators (Defibrillator) 12/2020
1	Biological Therapy 09/2017
1	Radiotherapy 11/2006